nodes	percent_of_prediction	percent_of_DWPC	metapath
Azelastine—CYP2C8—Spironolactone—dilated cardiomyopathy	0.179	0.409	CbGbCtD
Azelastine—ABCB1—Lisinopril—dilated cardiomyopathy	0.138	0.314	CbGbCtD
Azelastine—ABCB1—Spironolactone—dilated cardiomyopathy	0.121	0.277	CbGbCtD
Azelastine—Taste sweet—Furosemide—dilated cardiomyopathy	0.121	0.358	CcSEcCtD
Azelastine—KCNH2—purkinje fiber—dilated cardiomyopathy	0.08	0.452	CbGeAlD
Azelastine—KCNH2—endocardium—dilated cardiomyopathy	0.0412	0.233	CbGeAlD
Azelastine—CYP2C9—cardial valve—dilated cardiomyopathy	0.0335	0.189	CbGeAlD
Azelastine—Breast pain—Spironolactone—dilated cardiomyopathy	0.00881	0.0261	CcSEcCtD
Azelastine—Amenorrhoea—Spironolactone—dilated cardiomyopathy	0.00875	0.0259	CcSEcCtD
Azelastine—Ulcer—Spironolactone—dilated cardiomyopathy	0.00813	0.0241	CcSEcCtD
Azelastine—Dysaesthesia—Lisinopril—dilated cardiomyopathy	0.00726	0.0215	CcSEcCtD
Azelastine—Influenza-like symptoms—Lisinopril—dilated cardiomyopathy	0.00439	0.013	CcSEcCtD
Azelastine—Laryngitis—Lisinopril—dilated cardiomyopathy	0.00435	0.0129	CcSEcCtD
Azelastine—Mental disability—Furosemide—dilated cardiomyopathy	0.00363	0.0107	CcSEcCtD
Azelastine—Breast pain—Lisinopril—dilated cardiomyopathy	0.0036	0.0106	CcSEcCtD
Azelastine—Viral infection—Lisinopril—dilated cardiomyopathy	0.00348	0.0103	CcSEcCtD
Azelastine—KCNH2—cardiac ventricle—dilated cardiomyopathy	0.00347	0.0196	CbGeAlD
Azelastine—KCNH2—myocardium—dilated cardiomyopathy	0.00326	0.0184	CbGeAlD
Azelastine—Anaphylactoid reaction—Furosemide—dilated cardiomyopathy	0.00314	0.00928	CcSEcCtD
Azelastine—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.00312	0.00923	CcSEcCtD
Azelastine—Influenza like illness—Lisinopril—dilated cardiomyopathy	0.00305	0.00902	CcSEcCtD
Azelastine—Malaise—Spironolactone—dilated cardiomyopathy	0.00303	0.00897	CcSEcCtD
Azelastine—CYP1A1—cardiac ventricle—dilated cardiomyopathy	0.00293	0.0166	CbGeAlD
Azelastine—Urinary retention—Furosemide—dilated cardiomyopathy	0.00289	0.00854	CcSEcCtD
Azelastine—Discomfort—Spironolactone—dilated cardiomyopathy	0.00283	0.00837	CcSEcCtD
Azelastine—Confusional state—Spironolactone—dilated cardiomyopathy	0.00277	0.00818	CcSEcCtD
Azelastine—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.00274	0.00812	CcSEcCtD
Azelastine—Sleep disorder—Lisinopril—dilated cardiomyopathy	0.00263	0.00779	CcSEcCtD
Azelastine—Gastroenteritis—Lisinopril—dilated cardiomyopathy	0.00257	0.00761	CcSEcCtD
Azelastine—Eczema—Lisinopril—dilated cardiomyopathy	0.00254	0.0075	CcSEcCtD
Azelastine—Somnolence—Spironolactone—dilated cardiomyopathy	0.00244	0.00722	CcSEcCtD
Azelastine—Pollakiuria—Furosemide—dilated cardiomyopathy	0.00242	0.00717	CcSEcCtD
Azelastine—Atrial fibrillation—Lisinopril—dilated cardiomyopathy	0.0024	0.00711	CcSEcCtD
Azelastine—Anaphylactoid reaction—Lisinopril—dilated cardiomyopathy	0.00235	0.00697	CcSEcCtD
Azelastine—Arthritis—Lisinopril—dilated cardiomyopathy	0.00234	0.00694	CcSEcCtD
Azelastine—KCNH2—heart—dilated cardiomyopathy	0.00228	0.0129	CbGeAlD
Azelastine—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00226	0.00669	CcSEcCtD
Azelastine—Face oedema—Lisinopril—dilated cardiomyopathy	0.0022	0.00651	CcSEcCtD
Azelastine—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00217	0.00642	CcSEcCtD
Azelastine—Nasopharyngitis—Lisinopril—dilated cardiomyopathy	0.00204	0.00603	CcSEcCtD
Azelastine—Visual impairment—Furosemide—dilated cardiomyopathy	0.00202	0.00599	CcSEcCtD
Azelastine—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00202	0.00598	CcSEcCtD
Azelastine—Asthma—Lisinopril—dilated cardiomyopathy	0.00197	0.00583	CcSEcCtD
Azelastine—Eye disorder—Furosemide—dilated cardiomyopathy	0.00196	0.00581	CcSEcCtD
Azelastine—KCNH2—cardiac atrium—dilated cardiomyopathy	0.00195	0.011	CbGeAlD
Azelastine—Pruritus—Spironolactone—dilated cardiomyopathy	0.00194	0.00574	CcSEcCtD
Azelastine—Bronchospasm—Lisinopril—dilated cardiomyopathy	0.00194	0.00573	CcSEcCtD
Azelastine—CYP1A1—heart—dilated cardiomyopathy	0.00192	0.0109	CbGeAlD
Azelastine—Bronchitis—Lisinopril—dilated cardiomyopathy	0.00189	0.0056	CcSEcCtD
Azelastine—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00188	0.00555	CcSEcCtD
Azelastine—CYP2B6—heart—dilated cardiomyopathy	0.00187	0.0106	CbGeAlD
Azelastine—CYP2C9—heart—dilated cardiomyopathy	0.00185	0.0105	CbGeAlD
Azelastine—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.00183	0.00541	CcSEcCtD
Azelastine—Dizziness—Spironolactone—dilated cardiomyopathy	0.00181	0.00537	CcSEcCtD
Azelastine—Weight increased—Lisinopril—dilated cardiomyopathy	0.00179	0.0053	CcSEcCtD
Azelastine—Dysgeusia—Furosemide—dilated cardiomyopathy	0.00179	0.0053	CcSEcCtD
Azelastine—Vomiting—Spironolactone—dilated cardiomyopathy	0.00174	0.00516	CcSEcCtD
Azelastine—Rash—Spironolactone—dilated cardiomyopathy	0.00173	0.00512	CcSEcCtD
Azelastine—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00173	0.00511	CcSEcCtD
Azelastine—Vision blurred—Furosemide—dilated cardiomyopathy	0.00172	0.0051	CcSEcCtD
Azelastine—Headache—Spironolactone—dilated cardiomyopathy	0.00172	0.00508	CcSEcCtD
Azelastine—Agitation—Furosemide—dilated cardiomyopathy	0.00168	0.00497	CcSEcCtD
Azelastine—Haematuria—Lisinopril—dilated cardiomyopathy	0.00167	0.00495	CcSEcCtD
Azelastine—Epistaxis—Lisinopril—dilated cardiomyopathy	0.00166	0.0049	CcSEcCtD
Azelastine—Sinusitis—Lisinopril—dilated cardiomyopathy	0.00165	0.00487	CcSEcCtD
Azelastine—CYP1A1—cardiac atrium—dilated cardiomyopathy	0.00164	0.0093	CbGeAlD
Azelastine—Vertigo—Furosemide—dilated cardiomyopathy	0.00164	0.00486	CcSEcCtD
Azelastine—Nausea—Spironolactone—dilated cardiomyopathy	0.00163	0.00482	CcSEcCtD
Azelastine—Rhinitis—Lisinopril—dilated cardiomyopathy	0.00158	0.00468	CcSEcCtD
Azelastine—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.00156	0.00463	CcSEcCtD
Azelastine—Dry mouth—Furosemide—dilated cardiomyopathy	0.00152	0.00451	CcSEcCtD
Azelastine—Confusional state—Furosemide—dilated cardiomyopathy	0.0015	0.00445	CcSEcCtD
Azelastine—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.00149	0.00442	CcSEcCtD
Azelastine—Flushing—Lisinopril—dilated cardiomyopathy	0.00146	0.00433	CcSEcCtD
Azelastine—Tension—Lisinopril—dilated cardiomyopathy	0.00135	0.00398	CcSEcCtD
Azelastine—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.00134	0.00398	CcSEcCtD
Azelastine—Paraesthesia—Furosemide—dilated cardiomyopathy	0.00134	0.00397	CcSEcCtD
Azelastine—Nervousness—Lisinopril—dilated cardiomyopathy	0.00133	0.00394	CcSEcCtD
Azelastine—Back pain—Lisinopril—dilated cardiomyopathy	0.00133	0.00393	CcSEcCtD
Azelastine—Somnolence—Furosemide—dilated cardiomyopathy	0.00133	0.00393	CcSEcCtD
Azelastine—Vision blurred—Lisinopril—dilated cardiomyopathy	0.00129	0.00383	CcSEcCtD
Azelastine—Fatigue—Furosemide—dilated cardiomyopathy	0.00129	0.00381	CcSEcCtD
Azelastine—Pain—Furosemide—dilated cardiomyopathy	0.00128	0.00378	CcSEcCtD
Azelastine—Constipation—Furosemide—dilated cardiomyopathy	0.00128	0.00378	CcSEcCtD
Azelastine—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.00127	0.00377	CcSEcCtD
Azelastine—Malaise—Lisinopril—dilated cardiomyopathy	0.00124	0.00366	CcSEcCtD
Azelastine—Vertigo—Lisinopril—dilated cardiomyopathy	0.00123	0.00365	CcSEcCtD
Azelastine—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.00123	0.00364	CcSEcCtD
Azelastine—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.00122	0.00361	CcSEcCtD
Azelastine—Palpitations—Lisinopril—dilated cardiomyopathy	0.00121	0.00359	CcSEcCtD
Azelastine—Cough—Lisinopril—dilated cardiomyopathy	0.0012	0.00354	CcSEcCtD
Azelastine—Abdominal pain—Furosemide—dilated cardiomyopathy	0.00118	0.00349	CcSEcCtD
Azelastine—Body temperature increased—Furosemide—dilated cardiomyopathy	0.00118	0.00349	CcSEcCtD
Azelastine—Myalgia—Lisinopril—dilated cardiomyopathy	0.00117	0.00346	CcSEcCtD
Azelastine—Chest pain—Lisinopril—dilated cardiomyopathy	0.00117	0.00346	CcSEcCtD
Azelastine—Anxiety—Lisinopril—dilated cardiomyopathy	0.00116	0.00344	CcSEcCtD
Azelastine—Discomfort—Lisinopril—dilated cardiomyopathy	0.00115	0.00341	CcSEcCtD
Azelastine—Dry mouth—Lisinopril—dilated cardiomyopathy	0.00114	0.00338	CcSEcCtD
Azelastine—Confusional state—Lisinopril—dilated cardiomyopathy	0.00113	0.00334	CcSEcCtD
Azelastine—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.00112	0.00331	CcSEcCtD
Azelastine—Infection—Lisinopril—dilated cardiomyopathy	0.00111	0.00329	CcSEcCtD
Azelastine—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.0011	0.00325	CcSEcCtD
Azelastine—Tachycardia—Lisinopril—dilated cardiomyopathy	0.00109	0.00323	CcSEcCtD
Azelastine—Asthenia—Furosemide—dilated cardiomyopathy	0.00107	0.00317	CcSEcCtD
Azelastine—Pruritus—Furosemide—dilated cardiomyopathy	0.00106	0.00312	CcSEcCtD
Azelastine—Diarrhoea—Furosemide—dilated cardiomyopathy	0.00102	0.00302	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.00102	0.00302	CcSEcCtD
Azelastine—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.00101	0.00298	CcSEcCtD
Azelastine—ABCB1—heart—dilated cardiomyopathy	0.000999	0.00565	CbGeAlD
Azelastine—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.000998	0.00295	CcSEcCtD
Azelastine—Somnolence—Lisinopril—dilated cardiomyopathy	0.000996	0.00295	CcSEcCtD
Azelastine—Dizziness—Furosemide—dilated cardiomyopathy	0.000987	0.00292	CcSEcCtD
Azelastine—Fatigue—Lisinopril—dilated cardiomyopathy	0.000966	0.00286	CcSEcCtD
Azelastine—Pain—Lisinopril—dilated cardiomyopathy	0.000958	0.00283	CcSEcCtD
Azelastine—Constipation—Lisinopril—dilated cardiomyopathy	0.000958	0.00283	CcSEcCtD
Azelastine—Vomiting—Furosemide—dilated cardiomyopathy	0.000949	0.00281	CcSEcCtD
Azelastine—Rash—Furosemide—dilated cardiomyopathy	0.000941	0.00278	CcSEcCtD
Azelastine—Dermatitis—Furosemide—dilated cardiomyopathy	0.00094	0.00278	CcSEcCtD
Azelastine—Headache—Furosemide—dilated cardiomyopathy	0.000935	0.00277	CcSEcCtD
Azelastine—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.000923	0.00273	CcSEcCtD
Azelastine—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.000916	0.00271	CcSEcCtD
Azelastine—Nausea—Furosemide—dilated cardiomyopathy	0.000887	0.00262	CcSEcCtD
Azelastine—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.000885	0.00262	CcSEcCtD
Azelastine—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.000885	0.00262	CcSEcCtD
Azelastine—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.000825	0.00244	CcSEcCtD
Azelastine—Asthenia—Lisinopril—dilated cardiomyopathy	0.000803	0.00238	CcSEcCtD
Azelastine—Pruritus—Lisinopril—dilated cardiomyopathy	0.000792	0.00234	CcSEcCtD
Azelastine—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000766	0.00227	CcSEcCtD
Azelastine—Dizziness—Lisinopril—dilated cardiomyopathy	0.000741	0.00219	CcSEcCtD
Azelastine—Vomiting—Lisinopril—dilated cardiomyopathy	0.000712	0.00211	CcSEcCtD
Azelastine—Rash—Lisinopril—dilated cardiomyopathy	0.000706	0.00209	CcSEcCtD
Azelastine—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000705	0.00209	CcSEcCtD
Azelastine—Headache—Lisinopril—dilated cardiomyopathy	0.000702	0.00208	CcSEcCtD
Azelastine—Nausea—Lisinopril—dilated cardiomyopathy	0.000665	0.00197	CcSEcCtD
Azelastine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000114	0.00244	CbGpPWpGaD
Azelastine—HRH3—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000113	0.00243	CbGpPWpGaD
Azelastine—ABCB1—Allograft Rejection—FAS—dilated cardiomyopathy	0.000113	0.00242	CbGpPWpGaD
Azelastine—CYP1A1—PPARA activates gene expression—CD36—dilated cardiomyopathy	0.000113	0.00242	CbGpPWpGaD
Azelastine—HRH1—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.000112	0.00239	CbGpPWpGaD
Azelastine—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CD36—dilated cardiomyopathy	0.00011	0.00236	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.00011	0.00236	CbGpPWpGaD
Azelastine—HRH3—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.00011	0.00235	CbGpPWpGaD
Azelastine—HRH1—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.000108	0.00232	CbGpPWpGaD
Azelastine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—dilated cardiomyopathy	0.000107	0.00229	CbGpPWpGaD
Azelastine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000106	0.00227	CbGpPWpGaD
Azelastine—ADRA1B—LPA receptor mediated events—EGFR—dilated cardiomyopathy	0.000104	0.00223	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000104	0.00222	CbGpPWpGaD
Azelastine—HRH3—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000103	0.00221	CbGpPWpGaD
Azelastine—HRH1—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000103	0.00221	CbGpPWpGaD
Azelastine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000103	0.00221	CbGpPWpGaD
Azelastine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000102	0.00219	CbGpPWpGaD
Azelastine—ADRA1B—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000102	0.00219	CbGpPWpGaD
Azelastine—CYP1A1—PPARA activates gene expression—AGT—dilated cardiomyopathy	0.000101	0.00218	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.0001	0.00215	CbGpPWpGaD
Azelastine—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—AGT—dilated cardiomyopathy	9.93e-05	0.00213	CbGpPWpGaD
Azelastine—HRH3—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	9.78e-05	0.0021	CbGpPWpGaD
Azelastine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—dilated cardiomyopathy	9.7e-05	0.00208	CbGpPWpGaD
Azelastine—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—dilated cardiomyopathy	9.7e-05	0.00208	CbGpPWpGaD
Azelastine—ADRA1B—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	9.68e-05	0.00208	CbGpPWpGaD
Azelastine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	9.57e-05	0.00205	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	9.44e-05	0.00202	CbGpPWpGaD
Azelastine—HRH3—Signaling by GPCR—AGTR1—dilated cardiomyopathy	9.36e-05	0.00201	CbGpPWpGaD
Azelastine—ADRA1B—G alpha (q) signalling events—AGT—dilated cardiomyopathy	9.29e-05	0.00199	CbGpPWpGaD
Azelastine—HRH1—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	9.27e-05	0.00199	CbGpPWpGaD
Azelastine—CYP1A1—Aryl Hydrocarbon Receptor—TNF—dilated cardiomyopathy	9.24e-05	0.00198	CbGpPWpGaD
Azelastine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—dilated cardiomyopathy	9.24e-05	0.00198	CbGpPWpGaD
Azelastine—HRH1—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	9.24e-05	0.00198	CbGpPWpGaD
Azelastine—CYP1A2—Aryl Hydrocarbon Receptor—RAF1—dilated cardiomyopathy	9.02e-05	0.00193	CbGpPWpGaD
Azelastine—HRH3—Signaling by GPCR—ADRB2—dilated cardiomyopathy	8.88e-05	0.0019	CbGpPWpGaD
Azelastine—HRH1—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	8.76e-05	0.00188	CbGpPWpGaD
Azelastine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	8.74e-05	0.00187	CbGpPWpGaD
Azelastine—ADRA1B—GPCR ligand binding—AGTR2—dilated cardiomyopathy	8.66e-05	0.00186	CbGpPWpGaD
Azelastine—ADRA1B—GPCR ligand binding—CXCL2—dilated cardiomyopathy	8.66e-05	0.00186	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	8.58e-05	0.00184	CbGpPWpGaD
Azelastine—HRH1—G alpha (q) signalling events—AGT—dilated cardiomyopathy	8.41e-05	0.0018	CbGpPWpGaD
Azelastine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	8.31e-05	0.00178	CbGpPWpGaD
Azelastine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	8.3e-05	0.00178	CbGpPWpGaD
Azelastine—KCNH2—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	8.15e-05	0.00175	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—PSEN2—dilated cardiomyopathy	8.1e-05	0.00174	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	8.07e-05	0.00173	CbGpPWpGaD
Azelastine—ADRA1B—GPCR ligand binding—CXCR3—dilated cardiomyopathy	8.05e-05	0.00173	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—ANKRD1—dilated cardiomyopathy	8.04e-05	0.00172	CbGpPWpGaD
Azelastine—HRH1—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	7.92e-05	0.0017	CbGpPWpGaD
Azelastine—HRH1—GPCR ligand binding—CXCL2—dilated cardiomyopathy	7.84e-05	0.00168	CbGpPWpGaD
Azelastine—HRH1—GPCR ligand binding—AGTR2—dilated cardiomyopathy	7.84e-05	0.00168	CbGpPWpGaD
Azelastine—KCNH2—Neuronal System—RAF1—dilated cardiomyopathy	7.84e-05	0.00168	CbGpPWpGaD
Azelastine—ADRA1B—GPCR ligand binding—ADRB1—dilated cardiomyopathy	7.8e-05	0.00167	CbGpPWpGaD
Azelastine—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CD36—dilated cardiomyopathy	7.6e-05	0.00163	CbGpPWpGaD
Azelastine—HRH3—GPCR downstream signaling—RAC1—dilated cardiomyopathy	7.59e-05	0.00163	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—TAZ—dilated cardiomyopathy	7.56e-05	0.00162	CbGpPWpGaD
Azelastine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	7.52e-05	0.00161	CbGpPWpGaD
Azelastine—HRH1—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	7.51e-05	0.00161	CbGpPWpGaD
Azelastine—HRH1—GPCR ligand binding—CXCR3—dilated cardiomyopathy	7.29e-05	0.00156	CbGpPWpGaD
Azelastine—ABCB1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	7.28e-05	0.00156	CbGpPWpGaD
Azelastine—HRH3—GPCR downstream signaling—AGT—dilated cardiomyopathy	7.26e-05	0.00155	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—AGTR2—dilated cardiomyopathy	7.19e-05	0.00154	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—CXCL2—dilated cardiomyopathy	7.19e-05	0.00154	CbGpPWpGaD
Azelastine—ABCB1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	7.08e-05	0.00152	CbGpPWpGaD
Azelastine—ABCB1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	7.08e-05	0.00152	CbGpPWpGaD
Azelastine—HRH1—GPCR ligand binding—ADRB1—dilated cardiomyopathy	7.06e-05	0.00151	CbGpPWpGaD
Azelastine—HRH3—Signaling by GPCR—RAC1—dilated cardiomyopathy	6.9e-05	0.00148	CbGpPWpGaD
Azelastine—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—AGT—dilated cardiomyopathy	6.84e-05	0.00147	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—SDHA—dilated cardiomyopathy	6.84e-05	0.00147	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—CXCR3—dilated cardiomyopathy	6.69e-05	0.00143	CbGpPWpGaD
Azelastine—ADRA1B—GPCR ligand binding—AGTR1—dilated cardiomyopathy	6.66e-05	0.00143	CbGpPWpGaD
Azelastine—HRH3—Signaling by GPCR—AGT—dilated cardiomyopathy	6.59e-05	0.00141	CbGpPWpGaD
Azelastine—ABCB1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	6.59e-05	0.00141	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—ANKRD1—dilated cardiomyopathy	6.49e-05	0.00139	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—ADRB1—dilated cardiomyopathy	6.48e-05	0.00139	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—ANKRD1—dilated cardiomyopathy	6.36e-05	0.00136	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—ANKRD1—dilated cardiomyopathy	6.34e-05	0.00136	CbGpPWpGaD
Azelastine—ADRA1B—GPCR ligand binding—ADRB2—dilated cardiomyopathy	6.32e-05	0.00135	CbGpPWpGaD
Azelastine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—dilated cardiomyopathy	6.19e-05	0.00133	CbGpPWpGaD
Azelastine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—dilated cardiomyopathy	6.19e-05	0.00133	CbGpPWpGaD
Azelastine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	6.15e-05	0.00132	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—TAZ—dilated cardiomyopathy	6.1e-05	0.00131	CbGpPWpGaD
Azelastine—HRH1—GPCR ligand binding—AGTR1—dilated cardiomyopathy	6.03e-05	0.00129	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—ANKRD1—dilated cardiomyopathy	5.99e-05	0.00128	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—TAZ—dilated cardiomyopathy	5.98e-05	0.00128	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—TAZ—dilated cardiomyopathy	5.96e-05	0.00128	CbGpPWpGaD
Azelastine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—dilated cardiomyopathy	5.89e-05	0.00126	CbGpPWpGaD
Azelastine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—dilated cardiomyopathy	5.89e-05	0.00126	CbGpPWpGaD
Azelastine—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	5.77e-05	0.00124	CbGpPWpGaD
Azelastine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	5.77e-05	0.00124	CbGpPWpGaD
Azelastine—HRH1—GPCR ligand binding—ADRB2—dilated cardiomyopathy	5.72e-05	0.00123	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—TAZ—dilated cardiomyopathy	5.63e-05	0.00121	CbGpPWpGaD
Azelastine—HRH1—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	5.57e-05	0.00119	CbGpPWpGaD
Azelastine—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	5.57e-05	0.00119	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—AGTR1—dilated cardiomyopathy	5.53e-05	0.00119	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—SDHA—dilated cardiomyopathy	5.52e-05	0.00118	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—ANKRD1—dilated cardiomyopathy	5.49e-05	0.00118	CbGpPWpGaD
Azelastine—ABCB1—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	5.46e-05	0.00117	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—SDHA—dilated cardiomyopathy	5.4e-05	0.00116	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—SDHA—dilated cardiomyopathy	5.39e-05	0.00116	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—ADRB2—dilated cardiomyopathy	5.25e-05	0.00112	CbGpPWpGaD
Azelastine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	5.22e-05	0.00112	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—TAZ—dilated cardiomyopathy	5.17e-05	0.00111	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—SDHA—dilated cardiomyopathy	5.1e-05	0.00109	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—ANKRD1—dilated cardiomyopathy	4.9e-05	0.00105	CbGpPWpGaD
Azelastine—ADRA1B—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	4.89e-05	0.00105	CbGpPWpGaD
Azelastine—ADRA1B—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	4.89e-05	0.00105	CbGpPWpGaD
Azelastine—ABCB1—Allograft Rejection—TNF—dilated cardiomyopathy	4.79e-05	0.00103	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—ANKRD1—dilated cardiomyopathy	4.79e-05	0.00103	CbGpPWpGaD
Azelastine—ADRA1B—GPCR ligand binding—AGT—dilated cardiomyopathy	4.69e-05	0.001	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—SDHA—dilated cardiomyopathy	4.67e-05	0.001	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—TAZ—dilated cardiomyopathy	4.61e-05	0.000988	CbGpPWpGaD
Azelastine—HRH3—Signaling by GPCR—RAF1—dilated cardiomyopathy	4.57e-05	0.00098	CbGpPWpGaD
Azelastine—ADRA1B—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	4.55e-05	0.000975	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—ANKRD1—dilated cardiomyopathy	4.51e-05	0.000967	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	4.51e-05	0.000966	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—TAZ—dilated cardiomyopathy	4.5e-05	0.000965	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—ANKRD1—dilated cardiomyopathy	4.47e-05	0.000958	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—CXCL2—dilated cardiomyopathy	4.44e-05	0.000952	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—AGTR2—dilated cardiomyopathy	4.44e-05	0.000952	CbGpPWpGaD
Azelastine—HRH1—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	4.43e-05	0.000949	CbGpPWpGaD
Azelastine—HRH1—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	4.43e-05	0.000949	CbGpPWpGaD
Azelastine—ADRA1B—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	4.41e-05	0.000944	CbGpPWpGaD
Azelastine—HRH1—GPCR ligand binding—AGT—dilated cardiomyopathy	4.24e-05	0.000909	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—TAZ—dilated cardiomyopathy	4.24e-05	0.000909	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—TAZ—dilated cardiomyopathy	4.2e-05	0.000901	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—SDHA—dilated cardiomyopathy	4.17e-05	0.000894	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—CXCR3—dilated cardiomyopathy	4.13e-05	0.000885	CbGpPWpGaD
Azelastine—HRH1—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	4.12e-05	0.000883	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—RAC1—dilated cardiomyopathy	4.07e-05	0.000873	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—SDHA—dilated cardiomyopathy	4.07e-05	0.000872	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—AGTR2—dilated cardiomyopathy	4.02e-05	0.000862	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—CXCL2—dilated cardiomyopathy	4.02e-05	0.000862	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—ADRB1—dilated cardiomyopathy	4e-05	0.000857	CbGpPWpGaD
Azelastine—HRH1—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	3.99e-05	0.000855	CbGpPWpGaD
Azelastine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	3.95e-05	0.000848	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—AGT—dilated cardiomyopathy	3.89e-05	0.000834	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—SDHA—dilated cardiomyopathy	3.84e-05	0.000822	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—ANKRD1—dilated cardiomyopathy	3.82e-05	0.000819	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—SDHA—dilated cardiomyopathy	3.8e-05	0.000815	CbGpPWpGaD
Azelastine—ADRA1B—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	3.76e-05	0.000806	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—CXCR3—dilated cardiomyopathy	3.74e-05	0.000801	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—ADRB1—dilated cardiomyopathy	3.62e-05	0.000776	CbGpPWpGaD
Azelastine—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	3.62e-05	0.000775	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—TAZ—dilated cardiomyopathy	3.59e-05	0.00077	CbGpPWpGaD
Azelastine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	3.58e-05	0.000767	CbGpPWpGaD
Azelastine—ADRA1B—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	3.57e-05	0.000765	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—AGTR1—dilated cardiomyopathy	3.42e-05	0.000732	CbGpPWpGaD
Azelastine—HRH1—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	3.41e-05	0.00073	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—SDHA—dilated cardiomyopathy	3.25e-05	0.000696	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—ADRB2—dilated cardiomyopathy	3.24e-05	0.000695	CbGpPWpGaD
Azelastine—HRH1—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	3.23e-05	0.000693	CbGpPWpGaD
Azelastine—HRH3—Signaling by GPCR—EGFR—dilated cardiomyopathy	3.14e-05	0.000672	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	3.11e-05	0.000666	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—AGTR1—dilated cardiomyopathy	3.09e-05	0.000663	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	3.03e-05	0.000649	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—PSEN2—dilated cardiomyopathy	2.96e-05	0.000634	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	2.95e-05	0.000632	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	2.93e-05	0.000629	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	2.85e-05	0.000611	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	2.78e-05	0.000595	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	2.77e-05	0.000594	CbGpPWpGaD
Azelastine—ADRA1B—GPCR downstream signaling—RAC1—dilated cardiomyopathy	2.77e-05	0.000594	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	2.73e-05	0.000584	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—RAF1—dilated cardiomyopathy	2.7e-05	0.000579	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—PSEN2—dilated cardiomyopathy	2.68e-05	0.000574	CbGpPWpGaD
Azelastine—ADRA1B—GPCR downstream signaling—AGT—dilated cardiomyopathy	2.65e-05	0.000567	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CXCL2—dilated cardiomyopathy	2.63e-05	0.000563	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—AGTR2—dilated cardiomyopathy	2.63e-05	0.000563	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	2.54e-05	0.000545	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—RAC1—dilated cardiomyopathy	2.52e-05	0.000539	CbGpPWpGaD
Azelastine—HRH1—GPCR downstream signaling—RAC1—dilated cardiomyopathy	2.51e-05	0.000538	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	2.51e-05	0.000537	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	2.5e-05	0.000536	CbGpPWpGaD
Azelastine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	2.48e-05	0.000532	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	2.48e-05	0.000531	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CXCR3—dilated cardiomyopathy	2.44e-05	0.000523	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—AGT—dilated cardiomyopathy	2.4e-05	0.000515	CbGpPWpGaD
Azelastine—HRH1—GPCR downstream signaling—AGT—dilated cardiomyopathy	2.4e-05	0.000514	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CXCL2—dilated cardiomyopathy	2.38e-05	0.000509	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—AGTR2—dilated cardiomyopathy	2.38e-05	0.000509	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—ADRB1—dilated cardiomyopathy	2.36e-05	0.000507	CbGpPWpGaD
Azelastine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	2.36e-05	0.000506	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	2.32e-05	0.000497	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—RAC1—dilated cardiomyopathy	2.28e-05	0.000488	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	2.26e-05	0.000484	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	2.23e-05	0.000478	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CXCR3—dilated cardiomyopathy	2.21e-05	0.000473	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—AGT—dilated cardiomyopathy	2.18e-05	0.000466	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—ADRB1—dilated cardiomyopathy	2.14e-05	0.000459	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	2.03e-05	0.000436	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—AGTR1—dilated cardiomyopathy	2.02e-05	0.000433	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	1.98e-05	0.000425	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	1.93e-05	0.000414	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—ADRB2—dilated cardiomyopathy	1.92e-05	0.00041	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—GPX1—dilated cardiomyopathy	1.86e-05	0.000398	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—EGFR—dilated cardiomyopathy	1.85e-05	0.000397	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—AGTR1—dilated cardiomyopathy	1.83e-05	0.000392	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—CD36—dilated cardiomyopathy	1.81e-05	0.000388	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	1.74e-05	0.000372	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—ADRB2—dilated cardiomyopathy	1.73e-05	0.000372	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—RAF1—dilated cardiomyopathy	1.67e-05	0.000358	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	1.65e-05	0.000353	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—AGT—dilated cardiomyopathy	1.63e-05	0.000349	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—RAF1—dilated cardiomyopathy	1.51e-05	0.000324	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—GPX1—dilated cardiomyopathy	1.5e-05	0.000321	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	1.49e-05	0.000319	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—RAC1—dilated cardiomyopathy	1.49e-05	0.000319	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—GPX1—dilated cardiomyopathy	1.47e-05	0.000315	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—GPX1—dilated cardiomyopathy	1.47e-05	0.000314	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—CD36—dilated cardiomyopathy	1.46e-05	0.000313	CbGpPWpGaD
Azelastine—ABCB1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	1.44e-05	0.000308	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—CD36—dilated cardiomyopathy	1.43e-05	0.000306	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—CD36—dilated cardiomyopathy	1.43e-05	0.000306	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—AGT—dilated cardiomyopathy	1.42e-05	0.000304	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—GPX1—dilated cardiomyopathy	1.38e-05	0.000297	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—CD36—dilated cardiomyopathy	1.35e-05	0.000289	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—RAC1—dilated cardiomyopathy	1.35e-05	0.000288	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—AGT—dilated cardiomyopathy	1.31e-05	0.000282	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—AGT—dilated cardiomyopathy	1.29e-05	0.000276	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—AGT—dilated cardiomyopathy	1.29e-05	0.000276	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—AGT—dilated cardiomyopathy	1.28e-05	0.000275	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—GPX1—dilated cardiomyopathy	1.27e-05	0.000272	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—CD36—dilated cardiomyopathy	1.24e-05	0.000265	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—AGT—dilated cardiomyopathy	1.21e-05	0.00026	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.14e-05	0.000245	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—GPX1—dilated cardiomyopathy	1.13e-05	0.000243	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—AGT—dilated cardiomyopathy	1.11e-05	0.000238	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—GPX1—dilated cardiomyopathy	1.11e-05	0.000237	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—CD36—dilated cardiomyopathy	1.1e-05	0.000236	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—CD36—dilated cardiomyopathy	1.08e-05	0.000231	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—GPX1—dilated cardiomyopathy	1.04e-05	0.000223	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.04e-05	0.000222	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—GPX1—dilated cardiomyopathy	1.03e-05	0.000221	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—CD36—dilated cardiomyopathy	1.01e-05	0.000217	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—CD36—dilated cardiomyopathy	1.01e-05	0.000216	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—AGT—dilated cardiomyopathy	9.93e-06	0.000213	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—RAF1—dilated cardiomyopathy	9.86e-06	0.000211	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—AGT—dilated cardiomyopathy	9.69e-06	0.000208	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—AGT—dilated cardiomyopathy	9.14e-06	0.000196	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—AGT—dilated cardiomyopathy	9.06e-06	0.000194	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—RAF1—dilated cardiomyopathy	8.92e-06	0.000191	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—GPX1—dilated cardiomyopathy	8.83e-06	0.000189	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—CD36—dilated cardiomyopathy	8.6e-06	0.000184	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—AGT—dilated cardiomyopathy	7.74e-06	0.000166	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	6.81e-06	0.000146	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—EGFR—dilated cardiomyopathy	6.76e-06	0.000145	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	6.63e-06	0.000142	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—EGFR—dilated cardiomyopathy	6.12e-06	0.000131	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	5.97e-06	0.000128	CbGpPWpGaD
